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 ABSTRACT  
 
Extracorporeal Photochemotherapy (ECP) is an FDA-approved immunotherapy that has been treating 
cutaneous T cell lymphoma (CTCL) for over three decades. ECP’s antitumoral effect is a consequence of 
its generation of functional, physiologic, inflammatory monocyte-derived dendritic cells (MoDCs) and 
apoptotic, patient-derived tumor, which collectively, stimulate the adaptive immune system. Thus, in 
CTCL, ECP serves as a therapeutic dendritic cell vaccine against patient-specific neoantigens. This 
mechanism of action suggests ECP’s potential application to other solid tumors. We tested ECP’s 
applicability to head and neck squamous cell carcinoma (HNSCC) using a trackable antigen system 
involving the constitutively expressed HPV16 E7 oncoprotein. We hypothesized that ECP would 
successfully stimulate anti-epitope CD8 T cells, quantified by IFN-gamma ELISA, following processing 
and cross-presentation of HPV16 E7+ peptides and tumor cells by MoDCs. The trackable antigen system 
employed a commonly cited epitope, E7(11-19). E7+ short peptide and long peptide generated significant 
IFNg (p<0.0001) relative to the null control group. Tumor cell line SCC61 T+ (E7hi) demonstrated 
significantly elevated IFNg production relative to SCC61 T- (non-E7 expressing tumor), but only in the 
presence of platelets, plate-passage, and overnight incubation (p<0.0001). These results suggest an 
antigen-specific CD8 T cell response and reiterate critical ECP components that have previously been 
shown to facilitate immunogenic MoDC generation. Immunogenic MoDC phenotype was confirmed with 
flow cytometry of inflammatory surface markers and intracellular cytokines, all of which were generally 
upregulated following ECP. Overall, we have demonstrated a proof-of-principle for ECP’s therapeutic 
vaccination against HNSCC. This is particularly relevant because ECP offers unique synergistic potential 
with recently FDA-approved checkpoint inhibitors. 
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INTRODUCTION  
An improved understanding of the relationship between immune system dysfunction and the 
development, establishment, and progression of cancer has evolved the landscape of immunotherapy.1 In 
an immunocompetent host, if the immune system is able to recognize the cancer cell as “foreign” and 
avoid suppression, it should succeed in eradicating the malignancy. A high tumoral mutation rate 
increases the probability of generating non-synonymous mutations, and consequently, targetable 
neoantigens on the cell surface.1-3 Interestingly, extracorporeal photochemotherapy or extracorporeal 
photopheresis (ECP), an FDA-approved immunotherapy for advanced cutaneous T cell lymphoma 
(CTCL), serves as a therapeutic dendritic cell vaccine which generates a clinically significant cytotoxic T-
cell response against patient-specific neo-antigens.4,5 This unique capability theoretically extends ECP’s 
application to other malignancies4-8, particularly those with high mutation rates or poorly characterized 
molecular targets.2,3,9,10 
ECP Discovery  
Edelson and colleagues serendipitously discovered the clinical effects of ECP when they were devising a 
blood-directed palliative chemotherapy against CTCL, a group of non-Hodgkins lymphoma marked by 
skin infiltrating malignant T cells.11,12 The first patient treated with ECP in 1982 entered lifelong 
remission after only 3 monthly treatment cycles of 3% of the total CTCL cells.5 Furthermore, in the 1987 
phase I/II clinical study treating 37 resistant CTCL patients, although less than 5% of the patient’s 
malignant T cells were treated with photochemotherapy, 73% of the patients responded to treatment and 
experienced an average 64% decrease in cutaneous involvement. Remarkably, there were no serious side 
effects.11 As a result of this favorable trial, ECP was expeditiously approved by the FDA in 1988, and 
subsequently, CTCL was no longer deemed a universally fatal disease.5,12 
ECP’s Mechanism of Action 
The cellular and cytokine interactions involved in ECP’s immunogenic effect have slowly been defined 
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over the course of several decades since its invention. Edelson and colleagues surmised that the clinical 
effects of ECP could not be explained simply by the reduction in the population of circulating malignant 
cells, since less than 5% of the patients involved T cells were exposed to the photochemotherapy. ECP’s 
mechanism of action became even more nebulous after the medical community realized its beneficial 
immunosuppressive effects in organ transplant recipients (ie graft versus host disease or transplant 
rejection)13, suggesting bidirectionality of ECP’s immunomodulation. It was not until the discovery that 
ECP was able to generate two maturationally distinct subsets of dendritic cells, one immunogenic and one 
immunotolerizing4,5,14-16 that this seemingly paradoxical phenomenon was reconciled.  
Understanding of ECP’s immunogenic mechanism requires summarizing the therapy’s use in CTCL:  
(1) A portion of the patient’s whole blood is removed and the leukocyte fraction containing malignant 
CD4 T cells, healthy immune cells and platelets is isolated and combined with 8-methoxypsoralen (8-
MOP). 
(2) This cellular/chemotherapy mixture is exposed to UVA radiation as it passes through a 1mm channel 
within parallel plastic plates permeable to UVA. UVA light activates 8-MOP into the therapeutically 
active form capable of cross-linking DNA and thus inducing cell death through DNA damage. The 
photochemotherapy combination, UVA and 8-MOP (PUVA), is titratable, so that it can preferentially 
induce apoptosis of leukocytes (ie malignant cells in CTCL) while sparing other immune cell subsets such 
as monocytes and dendritic cells. 
(3) The cell mixture is returned to the patient, inducing an immunogenic response against the malignancy. 
The current understanding of ECP’s mechanism, deriving from years of scientific research, and endorsed 
by the ECP community at the recent meeting of the American Council of ECP17, is as follows. 
 
A. Platelet-Monocyte Interactions Produce Monocyte-Derived Dendritic Cells 
As the cells and plasma proteins pass through the parallel plates during ECP, fibrinogen coats the surface 
of the polystyrene flow chamber, and platelets subsequently adhere to the RGD domains of fibrinogen via 
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αIIβ3 and α5β1 receptors. The adherent/activated platelets translocate P-selectin among other proteins to 
their surface, which then binds monocytes via PSGL-1, facilitating monocyte tethering to the platelets, 
partial monocyte activation, and monocyte integrin receptor conformational changes. Further interactions 
between platelet ligands (including those containing RGD domains) and monocytes induce monocytes 
into the dendritic cell (DC) maturational pathway. Flow shear stresses imparted on tethered monocytes, 
and platelet density within the ECP plate, are significant factors in transforming monocytes into 
monocyte-derived dendritic cells (MoDCs).5,7,18  
B. PUVA Effect on Antigenicity and Dendritic Cell Maturation  
Concurrent to monocyte activation by platelets, 8-MOP becomes transiently photoactivated upon UVA 
exposure, covalently crosslinking pyrimidine bases of DNA and irreversibly damaging exposed nucleated 
cells. In ECP, the 8-MOP-UVA (PUVA) dosage is such that as few as three DNA-photoadducts per 
million DNA base pairs can induce universal lymphocyte apoptosis, while largely sparing the similarly 
exposed monocytes.5,19  
 
In CTCL patients, platelet-monocyte interactions produce functional, immunogenic MoDCs, which 
uptake PUVA-induced apoptotic malignant lymphocytes as a patient-specific antigen source, and produce 
a clinically significant CD8 T cell response against the malignancy.5,7,8,11,12,20 Within 24 hours of ECP, 
monocytes increase expression of 498 genes, nearly 20 of which are associated with mature DC function 
and identity, and over 60 encoding for transmembrane signaling proteins. In particular, RNA transcripts 
coding for MHC class II presentation (ie DC-LAMP), T cell costimulatory molecules (ie CD80, CD86, 
CD40), and other DC maturation markers (ie CD83, Decysin, FPRL2, CCR7, Decysin, OLR1) have been 
shown to be significantly upregulated.12 The immunogenic ECP-derived MoDCs upregulate surface 
expression of CD83, CD36, and MHC class II molecules, while reducing expression of CD14. Most 
importantly, these DCs acquire the functional capacity to mediate antigen cross-presentation to CD8 T 
cells and induce antigen-specific T cell proliferation.5,7 In addition, tumor cells treated with PUVA 
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upregulate MHC class I molecule (MHCI) expression and therefore, along with uptake by ECP-derived 
MoDCs, also enhance neoantigen peptide processing, improving the TCR-mediated CD8 T cell 
response.21 
In contrast, if monocytes themselves are sufficiently damaged by PUVA, they instead become immature, 
tolerogenic DCs.16,22-24 Under these conditions, PUVA-exposed monocytes upregulate the glucocorticoid-
induced leucine zipper GILZ (a hallmark of tolerogenic DCs), downregulate  costimulatory molecules 
CD80 and CD86, exhibit resistance to Toll-like receptor-induced maturation, increase production of IL-
10, and decrease production of IL-12.22 Additionally, PUVA can result in DC apoptosis, which furthers 
the immunosuppressive environment by inducing regulatory T cells. These cellular mechanisms are 
thought to underlie ECP’s immunotolerizing effects in GvHD and organ transplant patients.16  
C. MoDCs Generate an Antigen-Specific Response 
Current understanding of dendritic cell biology and ECP’s favorable clinical results in the absence of 
major systemic side effects suggest patient-specific antigen targeting by T cells, with recent murine and in 
vitro studies confirming this.4-6,8,20,25 Immunogenic ECP drives an adaptive immune response against  
patient-specific neoantigens, primarily through antigen-containing MoDC activation of CD8 T cells, 
though the presence of CD4 T cells and natural killer cells have also recently been shown to be significant 
factors in the anti-tumor effect.4 In tolerizing ECP, tolerogenic MoDCs are thought to achieve antigen-
specificity though uptake of non-self antigens arising from tissue damage in GvHD or transplant settings, 
and specific stimulation of regulatory T cells.5,16,22  
ECP’s Evolution 
To improve MoDC maturation and neoantigen uptake, processing, and docking onto APC’s MHC 
molecules, studied in the early 2000’s onward adopted a modified ECP protocol termed 
“Transimmunization” (TI), which includes an overnight incubation period of PUVA-treated cells.4,6,8 
During this period, spatial proximity of PUVA-damaged tumor cells with platelet-activated MoDCs 
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allows for more efficient DC uptake and processing of antigens from dying tumor cells, as evidenced by a 
60% clinical response rate of CTCL patients who failed standard ECP and/or other therapies during a 
clinical trial of Transimmunization for CTCL.26 Furthermore, ECP’s ability to provide a functional, 
therapeutic DC vaccine against undefined patient-specific neoantigens suggests therapeutic potential 
against other solid tumors. A modified transimmunization protocol where only tumor cells but not 
immune cells are exposed to PUVA, and where PUVA-treated tumor cells are subsequently co-incubated 
with MoDCs prior to re-injection, has recently demonstrated a significant CD8 T cell response against 
melanoma antigens both ex vivo and in vivo,4,20 with melanoma (YUMM1.7)-inoculated and colon 
carcinoma (MC38)-inoculated mice exhibiting significantly reduced tumor volume relative to untreated 
controls.4 
Potential Application to Head and Neck Squamous Cell Carcinoma  
To test ECP’s efficacy in other solid tumors, we sought a malignancy with poor prognosis and easily 
trackable antigens to demonstrate therapeutic vaccination proof-of-principle. Head and neck squamous 
cell carcinoma (HNSCC) accounts for 550,000 cases and 380,000 deaths annually. One-third of patients 
present with early stage disease (stage I or II). These patients, managed with primary surgery or 
radiotherapy (RT), carry a five-year overall survival rate of 70-90%. The remaining two-thirds of patients 
present with locoregionally advanced disease (stage III or IV) and are treated with a combination of 
surgery, RT, and/or chemotherapy. Unfortunately, 60% in this latter group experience local recurrence 
and 30% demonstrate distant metastases. Those with recurrent or metastatic disease have a median overall 
survival of 10 months.1,27-29 HNSCC’s robust immunosuppressive mechanisms explain the particularly 
poor prognosis, at least in part due to the following: generation of regulatory T cells, dysfunctional 
antigen processing and presentation, dysregulation of cytokine and chemokine pathways, and a hostile 
tumor microenvironment.1,27,30,31  
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HNSCC can be further classified into human papilloma virus (HPV) positive and negative entities, with 
25% of all HNSCC and up to 90% of oropharyngeal carcinoma cases being HPV positive.29,30,32 It is well 
established that carcinogenic strains of HPV are responsible for the constitutive synthesis of oncoproteins 
E6 and E7, inhibitors of tumor-suppressor proteins p53 and Retinoblastoma (Rb), respectively.33 Because 
these oncoproteins are uniquely expressed on malignant tissues, they have become attractive therapeutic 
targets,30,33-35 and at minimum, can serve as trackable tumor-specific antigens for demonstrating ECP’s 
applicability to HNSCC.  
 
We hypothesized that ECP could be a potent therapy against HNSCC given the recent success of adoptive 
tumor-infiltrating lymphocyte (TIL) transfer strategies in this disease.3,10,30,36 In fact, Stevanovic et al. 
found in patients an immunodominant T cell reactivity against neoantigens, rather than the canonical E6 
and E7 epitopes,3 which favorably plays into ECP’s unique mechanism of action.5 Moreover, PUVA’s 
ability to upregulate MHCI expression21 may partially overcome the immunosuppressive nature of 
HNSCC.1 Finally, the recent FDA-approval of checkpoint inhibitors directed against PD-1 and CTLA-4 
receptors on T cells further increased the ECP’s appeal, offering potential for immunotherapeutic 
synergism between a dendritic cell-based strategy and immunogenic T cell activation strategies.1 
 
Here, we investigated ECP’s potential to treat HNSCC through the in vitro generation of a CD8 T cell 
response against a well-established HPV16 E7 epitope using the TI protocol. In selecting a trackable 
antigen, we focused on HPV16 because it is the most commonly implicated HPV strain in HNSCC.29,30,32 
With respect to oncoprotein, we chose E7 instead of E6, given that it exhibits less sequence variation and 
has superior epitope binding affinity to HLA*A2:01, the most prevalent MHCI molecule in the United 
States and Europe.30,37,38 With respect to CD8 T cell receptors, we sought epitope specificity to E7(11-20) 
and E7(11-19), highly studied sequences with ability to stimulate CD8 T cells in vitro and in vivo.
38,39 We 
reasoned that if ECP is able to initially demonstrate successful proof-of-principle CD8 T cell response 
specifically against HPV antigens in HNSCC, then the therapy may similarly generate an in vivo response 
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against patient-specific HNSCC neoantigens, which are implicated in clinically effective anti-tumor 
responses.3,5,9 This is the first time ECP has been tested in the context of HNSCC.  
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STATEMENT OF PURPOSE  
This is a proof-of-principle project to determine ECP applicability to HNSCC by using a trackable 
antigen source, in particular, two commonly studied immunogenic HPV16 E7 epitopes.  
Specific Aims 
1. Generate a CD8 T cell line with TCR specificity to HPV16 E7(11-19) and E7(11-20) epitopes 
2. Demonstrate that the updated “Transimmune” version of ECP (TI) can generate an HPV16 E7 Ag 
specific CD8 T cell response using HPV16 E7 overlapping and long peptides 
3. Demonstrate that TI can generate an HPV16 E7 Ag specific CD8 T cell response using a HNSCC cell 
line expressing E7 protein 
4. Demonstrate that following TI, monocytes acquire a mature, immunogenic DC phenotype, which 
underlies successful Ag cross-presentation  
Hypothesis  
TI will generate functional, immunogenic MoDCs, defined by their ability to phagocytose, process, and 
cross-present HPV+ HNSCC antigens, thus stimulating CD8 T cells in an antigen-specific manner. 
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MATERIALS AND METHODS  
HPV16 E7 Antigen Sources  
Peptides. Short, long, and overlapping peptides of the HPV16 E7 protein were used as Ag sources. Short 
peptide (SP) can directly fit into the TCR groove, bypassing APC phagocytosis, processing, and loading 
onto MHCI. Because of this capacity to directly stimulate T cells, SP served as a positive control. In 
contrast, long and overlapping peptides served as the experimental Ags, as they require functioning APCs 
for CD8 T cell stimulation.39 Short peptides: 9mers (amino acid sequence: YMLDLQPET) and 10mers 
(amino acid sequence: YMLDLQPETT) were synthesized at Tufts School of Medicine. Long peptide 
(LP): HPV16 E7(1-30) was synthesized at Tufts School of Medicine. Overlapping peptide (OP): PepMix™ 
HPV 16 Protein E7, a commercially available pool of 22 peptides derived from a peptide scan (15mers 
with 11 aa overlap) was used (JPT Peptide Technologies). Nanoparticle encapsulation: Using a previously 
described protocol, LP and OP was encapsulated with PLGA, which has been shown to enhance APC 
phagocytosis and presentation of the MHCI-peptide complex.40 SIINFEKL (ie OVA257-264) and melanoma 
antigen gp100(25-33) were used as negative peptide controls. 
Cell Lines 
Two SCC61 cells, one transfected to express high levels of HPV16 E6/E7 proteins (SCC61 T+) and one 
non-transfected and naturally non-expressive (SCC61 T-), were grown in DMEM/F12 media (1:1) + 10% 
FBS + 0.4ug/ml hydrocortisone.41 The SCC090 cell line (SCC90), naturally expressing HPV16 E7 
protein, was purchased at ATCC and grown in MEM, 10%FBS, 2mM L-glutamine. Normal human 
fibroblasts (NHF), which served as a cell line based negative control for E7 Ag, and NHF line modified to 
express HPV16 E6/E7 proteins (NHF T+) which served as a non-tumoral cell line source of E7 Ag, were 
grown in DMEM, 10%FBS, 2mM L-glutamine. SCC61 T-, SCC61 T+, NHF, NHF T+ were generously 
donated by the Yarbrough Lab at Yale. All cell lines were grown with Pen/Strep and grown to 70-80% 
confluence, harvested with trypsinization, and centrifuged at 1400RPM for 7min prior to use. 
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Peripheral Blood Mononuclear Cells (PBMCs)  
PBMCs were obtained from healthy, HLA*A2:01+ human donors, in accordance with the guidelines of 
the Yale Human Investigational Review Board, and with informed consent obtained under protocol 
number 0301023636. Whole blood was collected at a ratio of 100ml whole blood to 500ul heparin, so as 
to prevent coagulation but preserve future platelet activation. Whole blood was gently layered over 
Isolymph (CTL Scientific Supply Corp.) at a ratio of 35ml:15ml, centrifuged for 30minutes at 1500rpm. 
Then, the buffy coat was collected, washed with PBS using the same centrifugation settings, and the 
PBMC pellet resuspended for use.  
CD8 T Cells 
Anti-HPV16 E7(11-20) CD8 T cells. CD8 T cells with anti-HPV16 E7(11-20) TCR specificity were obtained 
from a commercial line originating from a female HLA*A2:01+ donor (Astarte Biologics), and expanded 
using the rapid expansion protocol (below). Following expansion, CD8 T cell purity was determined with 
flow cytometry analysis (below). 
 
Anti-HPV16 E7(11-19) CD8 T cells. Transgenic CD8 T cells with anti-HPV16 E7(11-19) TCR specificity were 
generated from a healthy, middle-aged, male HLA-A2+ donor’s PBMC population (Supplementary 
Figure 1). CD8 T cells were isolated from PBMCs, transduced to co-express anti-E7(11-19) TCR, and 
expanded using a rapid expansion protocol (REP). Following expansion, CD8 T cell purity was 
determined with flow cytometry analysis. 
 
TCR retroviral constructs. A retroviral supernatant capable of transducing human T cells to co-express 
TCRs with high-affinity binding to the E7(11-19) epitope was generously donated by Dr. Christian Hinrichs 
and his colleagues (NCI). The supernatant contains MSGV1 retrovirus, modified to include TCR 
nucleotide sequences inserted into its retrovirus backbone and is codon-optimized for expression in 
human cells. Moreover, its human TCR constant regions are exchanged for mouse TCR constant regions, 
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allowing for easy flow cytometry confirmation of successful transduction. This retrovirus has been used 
in prior clinical trials (Gene Oracle) and its molecular structure has been extensively characterized.30 
 
T cell transduction. Retroviral transduction was carried out based on recommendations from the Hinrichs 
Lab. On day 1, human PBMCs were isolated from a healthy HLA-A2+ donor and CD8 T cells were 
isolated using negative selection (Miltenyi Biotec). CD8 T cells were seeded into three wells of a tissue-
culture 24-well plate at a ratio of 7.5x106 CD8 T cells per well, with each well containing 2ml media 
(50/50 media + 300 IU/mL IL2 + 50 ng/mL OKT3). On day 2, a non-tissue culture 24-well plate was 
coated with retronectin (Takara #T100A/B) at final concentration of 20 µg/ml in PBS (ie 500ul 
retronectin/well), wrapped and stored overnight at 4C. On day 3, the retronectin plate was centrifuged at 
2000xg at 32C for 1 hour, followed by retronectin solution aspiration and blockage with 2ml 2% BSA in 
PBS for 30min at room temperature (RT). The retroviral supernatant was spun for 10 minutes at 
1000RPM. The retronectin plate was washed 2x with 1ml/well PBS, with the PBS remaining until the 
viral supernatant was added. After the 0.5ml/well supernatant was added, the retronectin plate was plastic 
wrapped, and spun for 2000xg at 32C for 2 hours. At the 1.5hour mark, T cells from the other plate were 
harvested and counted. The retronectin plate’s supernatant was aspirated and 0.25x106 T cells were 
added/well in 1 ml of media (50/50 AIMV/RPMI + 300 IU/mL IL2). The plate was wrapped and spun for 
10min at 1500RPM with brake set at 1, and incubated overnight. On day 4, the transduced cells were 
transferred off the retronectin into a tissue culture-coated 24-well plated. On day 6, cells were transferred 
to the appropriate sized flask and replenished with T cell media. On day 7, flow cytometry was used to 
assess E7(11-19) TCR positivity (below). 
  
Cell Sorting. T cells were harvested, spun down for 10min at 1500RPM, supernatants were discarded, and 
the cells were resuspended. Fc block was added and cells were incubated for 15min on ice. Staining 
buffer (1xPBS w/3% BSA) was added, and cells were centrifuged and resuspended identically. Samples 
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were stained for anti-CD8-BV421, anti-CD3-APC, anti-mTCRb-FITC (clone: H57-597), anti-7AAD-
percp-cy5.5, with respective single stain controls; stained cells were incubated for 30min on ice. Cells 
were centrifuged and resuspended identically, passed through a 70um filter (Falcon), and brought up at a 
25x106/ml sorting buffer (1xPBS w/ 0.1% BSA). Live CD3/CD8/mTCR-β triple-positive were selected 
(BD FACSAria). 
 
Rapid Expansion Protocol (REP) of CD8 T cells. REP stimulates T cells with the monoclonal antibody 
OKT3 (anti-CD3), IL-2, and irradiated autologous or allogeneic feeder cells to expand lymphocytes up to 
1000-fold over 14 days. This protocol was used to expand both E7(11-19) and E7(11-20) CD8 T cells. 
Approximately 2x108 feeder cells (ie PBMCs) were obtained from 3 healthy HLA-A2+ donors using the 
methods above and subsequently irradiated with 4000cGy (Yale Cesium-137 irradiator) at a cell 
concentration of 50*106/ml on ice. 2x108 feeder cells were combined with 1-2x106  CD8 Tcells  in a T-150 
with the following “50/50” media components: 75ml “complete media” (10% human AB serum (Lonza), 
pen/strep, 2.5% HEPES in RPMI), 75ml AIM V media, 4.5ul OKT3 (1mg/ml), 75ul IL-2 (1300IU/ml), 
ciprofloxacin (10 ug/ml). This flask was incubated at 37C, 5% CO2 until day 5, during which 3/4 of the 
medium was aspirated without disturbing the settled cells, and replenished with fresh 50/50 medium (as 
above) but without OKT-3. From this point forward, when the viable cell count reached 0.6x106-
1x106/ml, the cells were split 1:2 and replenished with AIMV media with 5% human AB serum and 
1300IU/ml IL-2. Cell count was assessed every two days. The desired effector T cell population was 
confirmed with flow cytometry (below) and frozen down at 5x106/ml 10% DMSO aliquots in liquid 
nitrogen. 
 
Flow cytometry to characterize post-REP CD8 T cells. Flow cytometry was used to confirm the epitope-
specific T cell population following REP. Fixable apoptosis dye “zombie”-apc-cy7, anti-mTCRb-FITC, 
anti-E7(11-20) dextramer-PE, anti-CD8-PacBlue, anti-CD4-PE-Cy5.5, and anti-CD3-APC stains with 
respective IgG controls were used (Biolegend). Anti-HPV E7(11-19) CD8 T cells were identified based on 
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the live CD3/CD8/mTCRβ positive population. Anti-HPV E7(11-20) CD8 T cells were identified based on 
the live CD3/CD8/E7(11-20) dextramer positive population. Data were acquired with a Stratedigm flow 
cytometer (BD Biosciences) and analyzed with FlowJo software (FlowJo). 
 
Transimmunization (TI) procedure  
The TI employed closely followed a previously established protocol,4 but was adjusted for different cell 
lines. An overall schematic is available as Supplementary Figure 2. Briefly, PBMCs were combined 
with PUVA-treated tumor cells, plate-passaged together, and incubated overnight. For peptide Ag groups, 
PBMCs alone were passed over a plate and peptide was added directly to the overnight incubation dish. 
The effects of plate passage, platelets, and TI (ie plate passage and overnight incubation) on T cell 
stimulation were tested. Additionally, each PBMC + CD8 Tcell + Ag group had parallel Ag groups 
containing only CD8 T cells or only PBMCs. Allogenic PBMCs were used in E7(11-20) experiments while 
autologous PBMCs were used in E7(11-19) experiments. 
CD8 T cell Thaw (Day 0). CD8 T cells were thawed and spun down at 700 RPM for 7 minutes. They 
were counted and incubated in T-25 flasks with 20ml T cell media (5% human AB serum, pen/strep, 
2mM L-glutamine in AIMV) and 8ul/20ml media of 1300IU/ml IL-2 until Day 2. 
 
PUVA (Day 1). The PUVA dose was cell line specific and based on the minimum dosage required to 
induce 100% apoptosis. Apoptosis was assessed by proliferation cessation during a 10-day monitoring 
period under confocal microscopy. SCC61 T+, NHF T-, and NHF T+ were treated with 8 Joules(J)/cm2 
and 200ng/ml 8-MOP while SCC61 T-, SCC90 were treated with 4J/cm2 and 200ng/ml 8-MOP. NHF T+ 
served as non-tumoral cell source of E7 Ag while NHF T- served as a non-antigenic negative control cell 
line. Cell lines were trypsinized, centrifuged and brought up at a concentration of 2.5x106 cells/300ul 
FBS. They were incubated in the dark with respective amounts of 8-MOP for 20minutes. To prepare for 
UVA treatment, 12-well plates were pre-coated with FBS to prevent cell adhesion. When 8-MOP 
 14 
incubation was completed, FBS was aspirated from the wells, and each well received 2.5x106 cells. 
Finally, each cell line received their respective UVA dose. 
 
Plate passage (Day 1). For groups involving cell lines as an Ag source, PUVA treated cells were 
combined with 107 cells PBMCs for a total volume of 600ul FBS. For groups involving peptides as an Ag 
source or PBMC + Ag groups, up to 4x107 cells PBMCs were brought up in 600ul FBS. For all groups, 
two-thirds (400ul) of the 600ul were used to coat the micro-plates for an hour at 37C to maximize fibrin 
and platelet adhesion; the remaining one-third remained in the Eppendorf tube. Microplate tubing was 
coated with FBS to prevent cell loss. After one hour, 600ul of cells were passaged through the microplate 
at 0.09 ml/min using a syringe pump. After collecting cells into respective Eppendorf tubes, microplates 
were washed with FBS at 0.49 ml/min in order to maximize cell yield. Overall, plate passage closely 
followed a previously established protocol.4 
 
Overnight Incubation (Day 1). To maximize MoDC maturation and Ag uptake, cell groups were 
incubated overnight at 37C. After plate passage, cells were counted. The cell count across groups were 
normalized based on the group with the lowest yield, typically above 5x106 cells, and each cell group was 
transferred into a respective 35mm dish with 15% human AB serum in 2ml RPMI. Groups that were not 
plate-passaged were thrown into the 35mm at the same time as their plate-passaged counterparts. In 
general, peptides were added at 10uM concentration into their respective dishes; however, nanoparticle 
encapsulated particles were added at a concentration of 200ug NP/2ml RPMI, based on prior NP 
experiments.40 
 
CD8 T Cell Co-Culture (Day 2). The next day, PBMCs in 35mm dishes and effector CD8 T cells were 
harvested, spun down, brought up in TCM, and counted. All groups were seeded as triplicates in 96-well 
plates for a total volume of 200ul TCM/well. For PBMC + T cell + Ag groups, 100ul of 0.2x106 PBMCs 
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were combined with 100ul of 0.1x106 effector CD8 T cells. PBMC + Ag and T cell + Ag groups seeded 
0.2x106 PBMCs in 200ul TCM and 0.1x106 CD8 T cells in 200ul TCM/well, respectively. In the T cell + 
Ag groups, peptide Ags were added at 10uM as before, and cell lines were PUVA treated and added in 
proportional numbers to their respective day 1 groups. Coincubation in the 96-well plates lasted 72 hours. 
 
Platelet depletion and “No TI”. In experiments involving transgenic CD8 T cells, the immunogenic 
contributions of platelets and TI were investigated. On day 1, platelets were depleted using CD61 
microbeads (Miltenyi Biotec) following PBMC isolation. Platelet depletion was confirmed using a 
Hemavet (Drew Scientific, Inc.), with a threshold of <104/ul considered successful depletion. Moreover, 
autologous serum (BD Vacutainer) was used for overnight incubation media. Subsequent experimental 
distribution of platelet-containing and platelet-depleted PBMCs was the same as above.  The “no TI” 
effect was explored by acquiring fresh PBMCs on day 2 and platelet-depleting a portion of them as done 
with TI, and adding them to a PBMC + T cell + Ag co-culture without plate passage and overnight 
incubation. “No TI” PBMCs were distributed to their respective groups as described in the “CD8 T Cell 
Co-Culture” section above. 
  
Monocyte Isolation. To simplify the APC-T Cell co-culture system and background IFNg noise, 
monocytes were isolated from donor PBMCs using the Pan Monocyte Isolation Kit (Miltenyi Biotec) per 
manufacturer’s recommendations. In the E7(11-20) system, monocytes were purified either on the day of 
PBMC isolation or after overnight incubation and prior to 96-well plate transfer. In the E7(11-19) system, 
monocytes were purified immediately following PBMC isolation. 
 
Cell Stimulation Readouts 
IFNg ELISA to measure CD8 T cell stimulation. After 72 hour co-cultures, the 96-well plates were spun 
down at 2000RPM for 10min at 4C. 180ul of supernatant were transferred into new 96-well plates, 
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wrapped, and frozen at -80C. Supernatants were analyzed with ELISA for interferon-γ (IFNg) production 
(BioLegend), which signifies CD8 T cell stimulation.30,42 The ELISA was run according to vendor 
guidelines and analyzed with the Spectromax reader. 
 
Flow cytometry to characterize phenotypic changes in monocytes after TI. The following surface markers 
which characterize MoDC maturation4,12,43 used to stain PBMC following TI treatment, per 
manufacturer’s instructions: CD80-FITC, CD83-APC, CD86-PE, HLA ABC-APC, HLA-DR-
APCEeFlour 780, CD11c-PE/Cy7, CD14-PacBlue, ICAM1-FITC, PLAUR-PE (BioLegend). An 
intracellular staining kit (BD Biosciences) was used to characterize associated chemokine expression with 
the following stains: CXCL5-PE, MCP-1-APC (BD Biosciences). Singlet, live, CD11c/CD14+ were 
gated on. Relative surface marker expression was quantified by change in mean fluorescent intensity 
(MFI) or by percentage of positive cells, as most appropriate to the stain. MFI was calculated as the 
intensity difference between stain and IgG. Percentage of positive monocytes was used to track 
populations expressing intracellular chemokines or surface CD80. 
 
Flow cytometry to characterize PD-1 expression following T cell stimulation. PD-1 is a recently 
discovered surrogate for neoantigen-specific CD4 and CD8 T cell stimulation3,36,44-46 and is therefore 
useful to ECP experiments, which involve mounting an adaptive immune response to undefined 
neoantigens. PD-1-PacBlue staining was used in conjunction with zombie-APC-Cy7, CD3-PE, CD4-
APC, CD8-FITC, with corresponding IgGs (BioLegend) following 2 day stimulation with OKT-3 (30ul 
of 1mg/ml stock per 2ml media) and IL-2 (1300IU/ml) of PBMCs. 
  
Statistics 
Statistical analyses were performed with Prism 8 (GraphPad Software). Depending on the experiment, 1-
way or 2-way ANOVA with Holm-Sidak’s multiple comparisons test were used to determine statistically 
significant IFNg production with respect to antigen, nanoparticle, and/or plate-passage effects. Tukey’s 
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multiple comparison tests were used to determine statistically significant differences in TI permutations in 
the E7(11-19) system. A P value of less than 0.05 was considered significant.  
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RESULTS 
REP generates a large population of CD8 T cells with Desired TCR specificity. 
To assess TI’s APC cross-presentation efficiency, we first needed to generate two large populations of 
epitope-specific CD8 T cells using REP. Anti-HPV16 E7(11-20) CD8 T cells were expanded 200-fold from 
a commercially available 2 million cell aliquot, of which approximately 81% were viable epitope-specific 
CD8 T cells. Following REP, cells were 95% viable, with E7(11-20) CD8 T cells comprising two-thirds of 
the compartment (Figure 1A). Since the physiological relevance of the E7(11-20) epitope is not universally 
accepted by the HPV research community38, we also generated in-house anti-HPV16 E7(11-19) CD8 T cells, 
and in this iteration, we sought a higher cell purity. After cell sorting, we obtained 1 million cells, nearly 
100% of which were E7(11-19) CD8 T cell. After REP, cells were expanded 150-fold; up to 93% were 
viable, with E7(11-19) CD8 T cell comprising 95% of the compartment (Figure 1B). 
  
CD8 T cells release IFNg upon direct stimulation with SP. 
Following generation of epitope-specific CD8 T cell populations, we confirmed T cell functionality in the 
simplest IFNg assay, cognate SP stimulation. Both E7(11-19) and E7(11-20) T cell lines demonstrated 
appropriate IFNg release upon direct TCR stimulation with the appropriate SP. E7(11-20) T Cell cultures 
with antigen showed significant IFNg production exclusively with SP (Figure 2A: p=0.012; Figure 2B: 
p<0.0001). In contrast, non-specific gp100 or SIINFEKL peptides, or E7+ Ag sources requiring APC 
processing were not able to directly stimulate E7(11-20) T cells (p>0.99; Figure 2). E7(11-19) transgenic CD8 
T cells also demonstrated significant IFNg release against their cognate SP (Figure 2C: p<0.0001). 
  
Co-culture of PBMC with E7(11-20) CD8 T cells and E7 Ags results in non-specific IFNg production. 
After demonstrating that our CD8 T cell lines could be stimulated with SP, we began TI testing of the 
E7(11-20) system to demonstrate APC-mediated Ag cross-presentation. PBMC + Ag cultures were run in 
parallel to the co-cultures to determine non-specific IFNg production (Figure 3), set as the dotted lines in 
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Figure 4. E7(11-20) CD8 T cells co-cultured with PBMC and peptide Ags (Figure 4A), did not 
significantly increase their IFNg production relative to the “null” (ie no Ag addition) group (p>0.98). 
When testing cellular E7 sources with the E7(11-20) T cell line (Figure 4B), again, there was no significant 
increase in IFNg production relative to the “null” group (p>0.98). Nanoparticle encapsulation and plate-
passage did not significantly increase IFNg production (p>0.98 for both).  Given that one-third of the 
“E7(11-20) CD8 T cells” added to the co-cultures were not epitope-specific (Figure 1), and the non-
autologous co-culture system, we suspected that high IFNg levels even in the “null” control group were 
due to cross-reactivity between the impure compartment of E7(11-20) CD8 T cells and donor PBMCs. To 
minimize non-specific IFNg release, the peptide Ag experiment was repeated by isolating monocytes, the 
APC progenitor, from PBMC donors. The PBMC + E7(11-20) T cell + Ag experiment was run in parallel 
with the monocyte + E7(11-20) T cell + Ag experiment; corresponding monocyte groups had up to ~40x 
reduction in IFNg release, confirming our hypothesis of non-specific allogenic cross-reactivity in this 
system (data not shown). Initially, we planned to purify and REP E7(11-20) CD8 T cells for repeat 
experiments, but after speaking with HPV experts at the NCI (ie Dr. Christian Hinrichs and colleagues), 
we decided to instead move forward with the co-culture system involving E7(11-19) CD8 T cells, as  
E7(11-19), and not E7(11-20), is a naturally expressed epitope in HPV16 carcinoma. Additionally, this system 
used autologous PBMC as the source of APCs to minimize nonspecific reactivity.38  
Co-culture of PBMC with E7(11-19) CD8 T cells and E7 Ags results in Ag-specific IFNg production. 
Overall, all E7+ groups seemed to selectively produce IFNg in the E7(11-19) system, suggesting successful 
TCR stimulation by direct exogenous loading as well as through APC-internalization/cross-presentation. 
First, a preliminary peptide stimulation assay was run comparing “null” no peptide, SP, and LP antigens 
in PBMC + E7(11-19) T cell + Ag co-cultures (Figure 5A). In this assay, autologous PBMCs were isolated 
and incubated overnight with 25uM of the relevant Ag, and the next day were transferred to a 96-well 
plate for 72 hour co-culture with T cells. Both SP and LP groups demonstrated over 40x IFNg production 
relative to the null group (p<0.0001). Further, the LP group produced significantly more IFNg than the SP 
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group (p<0.05). Next, a preliminary tumor stimulation assay was run comparing SCC61 T+ (Figure 5B) 
and SCC61 T- tumor cells as Ag sources (Figure 5C), and investigating the role of platelets in antigen-
specific T cell stimulation. Following PBMC isolation, a portion of PBMC was platelet-depleted, and 
additionally, purified monocytes with and without platelets were prepared from PBMCs. 5x106 PBMCs 
with or without platelets were pulsed overnight with 2.5x106 PUVA-treated tumor cells prior to co-culture 
with E7(11-19) T cells. Significant IFNg release (p<0.0001) exclusively required the presence of platelets 
and an E7+ antigen source (Figure 5B). This preliminary experiment suggested that Ag from tumor cells 
could be efficiently cross-presented to anti-tumor T cells. 
Following the initial confirmation of successful E7(11-19) T cell line stimulation with peptide and cellular 
antigens, a larger experiment investigating the role of TI (ie plate passage and overnight incubation) and 
platelets (PLT) in peptide and tumor Ag presentation was conducted (Figure 6). First, corresponding TI 
permutations of Ag groups were compared to that of the null group; the statistically significant 
differences are mentioned below. Negative control groups (null and SIINFEKL) exhibited similarly 
(p>0.78) minimal IFNg release across all tested TI groups. In contrast, positive control SP produced over 
10x the maximum IFNg observed in the null group (red vertical asterisks; p<0.0001). With respect to LP, 
PLT-/TI- and PLT+/TI- groups demonstrated significantly elevated IFNg (red vertical asterisks; 
p<0.0001). Finally, the high E7-expressing SCC61 T+ tumor cell group demonstrated significantly 
elevated IFNg production in the PLT+/TI- (p=0.043) and PLT+/TI+ (p<0.0001) setups. Thus, groups 
containing E7+ peptide and tumor cells demonstrated antigen-specific CD8 T cell stimulation, as shown 
in the preliminary experiment. 
To account for potential tumor-influenced inflammatory cytokine production47, IFNg profiles of the E7 
expressing groups were compared to those of the negative control cell line, SCC61 T-. The SCC90 group 
produced significantly less IFNg (p=0.039) in the PLT-/TI+ permutation but otherwise produced 
comparable levels to SCC61 T- (p>0.09). Notably, “full TI” SCC61 T+ (ie PLT+/TI+) produced 
significantly higher IFNg than its corresponding SCC61 T- group (red vertical asterisks; p<0.0001). 
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However, whereas the IFNg of the PLT+/TI- SCC61T+ was significantly higher than the null group 
(mentioned above), IFNg was similar to that of SCC61 T- (p=0.103). In this more conservative statistical 
analysis, the E7 expressing SCC61 T+ demonstrated antigen-specific CD8 T cell stimulation, but only 
with the “full TI” effect, underscoring the importance of platelets, plate-passage, and overnight incubation 
in producing inflammatory APCs capable of cross-presentation. Also of note, although the E7 protein is 
one of tens of thousands of proteins expressed within the SCC61 T+ cell line, its cross-presentation 
efficiency was remarkably efficient (nearly 50% as potent as pure peptide Ag preparations), confirming 
tumor-derived proteins as a viable source of personalized Ags for potential TI-based DC vaccinations in 
HNSCC. 
We hypothesized that the increasing absence of critical “full TI” components (ie platelets (PLTs) or “TI” 
= plate-passage & overnight incubation) should progressively decrease Ag cross-presentation and thus 
CD8 T cell stimulation.4,18 Tukey’s multiple comparison tests revealed significant differences in IFNg 
release between TI permutations in the SCC61 T+ group (Figure 6: blue asterisks). Following the 
expected trend, PLT+/TI+ resulted in superior cross presentation relative to PLT+/TI- (p=0.001), PLT-
/TI+ (p<0.0001), and PLT-/TI- (p<0.0001). SP (blue asterisk; p<0.017) and LP (blue asterisks; p<0.003) 
groups also exhibited significant variability across TI permutations, but not in the expected trend. Instead, 
there was higher T cell stimulation in the absence of TI, independent of the presence or absence of 
platelets. Given that both direct stimulation and cross-presentation requiring E7 peptide Ags demonstrated 
this phenomenon, CD8 T cell peptide stimulation results were likely confounded by proteolytic 
degradation (see discussion). 
TI, platelets, and E7 Antigen sources induce a pro-inflammatory MoDC phenotype. 
Monocytes in the E7(11-19) system were phenotyped for expression of the following inflammatory DC 
markers using a previously described panel4 including: CD80, CD83, CD86, HLA-ABC, HLA-DR, 
ICAM1, PLAUR, CXCL5, and MCP-1 (Figure 7). Platelet-depleted and platelet-containing monocytes 
that had undergone TI (ie plate-passage and overnight incubation) with LP or with SCC61 T+ were 
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compared to monocytes from fresh PBMCs. The TI effect alone, regardless of Ag source or platelets, 
ostensibly resulted in an increased expression of every inflammatory marker tested except for HLA-ABC; 
monocytes undergoing TI with SCC61 T+ showed less relative surface expression of HLA-ABC. This 
seemed to be a phenomenon specific to tumor cell Ag, as monocytes in parallel LP and null groups 
instead exhibited increased surface density of MHCI (Figure 7B). Furthermore, the presence of platelets 
enhanced the degree of inflammatory marker expression across all parallel Ag groups except for MCP-1. 
Platelet-depleted null and SCC61 T+ groups exhibited higher MCP-1 expression than respective platelet-
containing groups (Figure 7I). The groups with SCC61 T+ cells as antigen source showed the smallest 
upregulation of CD80, CD83, CD86, HLA-ABC, HLA-DR, and ICAM1 relative to null or LP groups 
(Figures A-D, F-G). On the other hand, SCC61 T+ monocytes exhibited the highest PLAUR surface 
expression (Figure 7E), and a distinctly larger subset of SCC61 T+ cell-pulsed monocytes were positive 
for intracellular chemokines CXCL5 and MCP-1 (Figures 7H-I).  
PD-1 can be used as surrogate for T cell stimulation. 
As previously mentioned, immunodominant antitumor T cell responses in HPV+ cancers are directed 
against neoantigens, and these TILs have been shown to reliably express PD-1. Given ECP’s production 
of a neoantigen-based T cell response, we established a PD-1 staining system to detect populations of 
stimulated CD4 and CD8 T cells in future experiments involving undefined patient neoantigens. 
Following 2-day stimulation of healthy donor PBMCs with IL-2 and OKT-3, a potent CD3 receptor 
stimulator, 50% of the CD8 T cells were PD-1+, whereas unstimulated controls were only 7% PD-1+. 
CD4 T cells similarly exhibited an increase in PD-1+ from 12% to 57% after 2-day stimulation (Figure 
8). At the time of this submission, post-stimulation PD-1 expression in HNSCC donor PBMCs has not yet 
been successfully determined. 
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DISCUSSION 
We embarked on a proof-of-principle project to determine the potential of modified ECP procedure 
termed “transimmunization” (TI) to treat HNSCC, an entirely novel application of this immunotherapy. A 
miniaturized ECP system4 was adopted to test whether CD8 T cells could be stimulated in vitro following 
APC cross-presentation of trackable HNSCC antigens, specifically, two commonly cited HPV16 E7 
protein epitopes.38,39,48 This work builds upon recent literature demonstrating ECP’s capacity to generate a 
significant CD8 T cells in response to melanoma antigens in vitro20 and in a murine model.4 Given the 
crucial role of CD8 T cells in HNSCC regression and ECP’s intrinsic ability to activate a cytotoxic T cell 
response towards patient-specific neoantigens, successful proof-of-principle would point to ECP’s utility 
in providing a functional, therapeutic dendritic cell vaccine against undefined HNSCC antigens. 
We first tested ECP’s ability to stimulate E7(11-20) CD8 T cells since these readout cells were readily 
available commercially. Unfortunately, this system produced a large degree of non-specific IFNg and 
therefore could not be studied. We believe allogeneic immunoreactivity49 (ie PBMC donor vs 67% pure 
commercial donor CD8 T cell with non-uniform TCR specificity) was a large contributor to the 
generation of IFNg observed in the PBMC + E7(11-20) T cell + Ag cultures; following monocyte isolation, 
monocyte + E7(11-20) T cell + Ag cultures generated an order of magnitude less of IFNg. To minimize 
future confounders, we planned to sort for a positive population E7(11-20) T cells and repeat experiments 
with monocyte depletion, as previously described.20 However, separately, there was a major concern of 
poor natural cross-presentation of the HPV16 E7(11-20) epitope in human cells.
30 In fact, Riemer et al. 
demonstrated with MS3 Poisson detection mass spectrometry that the HPV16 E7(11-19) epitope, and not the 
HPV16 E7(11-20) epitope, was the highly-conserved peptide naturally complexed with HLA-A*0201, and 
able to direct T cell-mediated tumor cytolysis.38 The immunologic relevance of the HPV16 E7(11-20) 
epitope was initially inferred from in silico predictions, HLA-synthetic peptide binding studies, and 
peripheral T cell functional activation assays, and not true identification of E7(11-20)-MHCI complexes. In 
retrospect, the numerous failed clinical therapeutic vaccine trials of the early 2000’s employing HPV16 
 24 
E7(11-20) antigen support this notion.
35,38,39  
In the second phase of the project, we switched to an entirely autologous system involving the HPV16 
E7(11-19) epitope to avoid the confounding factors mentioned above. First, a high purity transgenic CD8 T 
cell line co-expressing a high avidity anti- HPV16 E7(11-19) TCR was generated.
30 Functionality was 
confirmed by generation of IFNg with direct SP stimulation (Figure 2C). Interestingly, LP also 
stimulated T cells in the absence of antigen-presenting cells, far more so than the negative control 
irrelevant peptides in the T cell + Ag culture, likely suggesting degradation of LP into SP following 
immune cell death and release of proteases into the supernatant (Figure 2C).50 In theory, proteolytic 
degradation of SP can diminish CD8 T cell stimulation, while proteolytic degradation of LP can either 
enhance or decrease stimulation, depending on the amino acid sequences of the resultant peptides (eg LP 
degradation into E7(11-19) SP might increase T cell stimulation). This phenomenon may explain the 
significant variation in IFNg production in the SP and LP groups across different experiments (Figure 2C 
vs Figure 5A vs Figure 6). In addition, it would reconcile significant IFNg variability across ECP 
permutations (Figure 6) despite the fact that SP-mediated T cell stimulation is independent of functional 
APC internalization and cross-presentation.51 Cell passage through the ECP device itself may damage 
immune cells and cause the release of proteases. This theory also addresses LP’s seemingly inconsistent 
generation of IFNg (Figure 6). LP requires functional internalization by APC and presentation to CD8 T 
cells and therefore should show a progressive increase in T cell stimulation as more DC-generating ECP 
components are incorporated into the experiment.4,6,12,18,20 Instead, for example, the PLT-/TI- LP group 
produced significantly more IFNg than PLT+/TI+ LP and PLT-/TI+ LP groups (Figure 6; p<0.0001).  
Overall, PBMC + T cell + Ag assay results suggested successful cross-presentation of the E7(11-19) tumor-
relevant epitope to specifically activate CD8 T cells. Peptide stimulations (Figures 5A, 6) demonstrated 
varying degrees of stimulation with LP, as explained above. Tumor cell line stimulations were 
particularly successful with respect to SCC61 T+, confirming cross-presentation efficiency of tumor-
derived E7 Ag (Figures 5B-C, 6). Tumor cell lines SCC61 T- (negative control) and SCC90 did not 
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produce significant quantities of IFNg. In fact, the SCC90 cell line that is reported to naturally express the 
E7 protein engendered a similar or inferior T cell stimulation as the SCC61 T- cell line without E7 
expression (Figure 6). Because RT-PCR and immunoblotting was not completed at the time of this 
submission, E7 expression was not quantified across the tumor cell lines. SCC90’s inferior antigenicity is 
likely a result of superior immune evasion strategies, including downregulation of MHCI, downregulation 
of E7 protein translation, and/or mutations of other components of cellular cross-presentation 
machinery.2,27,31 In contrast, the SCC61 T+ line, theoretically expressing the highest amount of E7, was 
able to clearly able to demonstrate APC internalization and cross-presentation to epitope-specific T cells 
(Figure 5B vs 5C); this efficiency was maximized with the full TI effect (Figure 6). In other words, the 
presence of platelets, plate-passage, and overnight incubation significantly contributed to antigen cross-
presentation (Figure 5B vs 5C; Figure 6), results in agreement with prior literature.4,6,20  
Successful cross-presentation in peptide-based and tumor cell assays was supported by evidence of 
mature, inflammatory DC phenotype expression by monocytes following TI (Figure 7). In general, all 
immunogenic surface markers and intracellular chemokines were upregulated in TI-treated monocytes 
relative to fresh untreated monocytes. Moreover, the presence of platelets enhanced the expression of 
every inflammatory marker except MCP-1 (Figure 7I), further corroborating the importance of platelets 
in the TI/APC-maturation effect. Interestingly, monocytes of the tumor (SCC61 T+) overnight incubation 
group appeared to demonstrate the smallest increase in surface markers, and in fact, these cells displayed 
less MHCI (HLA-ABC) than fresh monocytes. However, this is not to suggest that monocytes co-
incubated with SCC61 T+ cells did not mature into inflammatory DCs. Instead, these monocytes/MoDCs 
were likely in the process of phagocytosing large apoptotic tumor cells, and subsequently internalized 
large segments of their cell membranes displaying these markers.52,53 Peptide pinocytosis or receptor-
mediated endocytosis, which rely on internalizing a smaller proportion of the cell membrane, would likely 
have a significantly lesser effect on cell surface marker expression.52,53 In contrast, internalization of 
whole tumors led to largest increase of inflammatory chemokine expressing monocytes/MoDCs 
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populations  (CXCL5+ (>50%) and MCP-1+ (>33%)) confirming the immunogenicity of apoptotic whole 
tumors, perhaps through DAMP activation.47 
Limitations and Future Directions 
The initial results have been encouraging, demonstrating successful stimulation of antigen-specific T cells 
by apoptotic tumor cell-pulsed, ECP-treated antigen presenting cells. T cell stimulation experiments will 
be repeated to improve statistical power. Other HPV+ E7 expressing tumor cell lines, including cervical 
cancers30, will be tested to further showcase ECP’s ability to produce an antigen-specific immunogenic 
response across several malignancies. In the most clinically relevant in vitro model, we will attempt to 
reproduce our experimental setup using a fully autologous system of HNSCC patient PBMCs, surgically-
removed tumors, and/or patient-derived tumor-infiltrating lymphocytes. If ECP is able to stimulate donor 
tumor-reactive T cells with patient-derived neoantigens, then such reactive cells should be double-
positive for IFNg and PD-1, as previously shown for in vivo tumor targeting strategies.3,36 Furthermore, 
these findings can be validated in murine in vivo tumor experiments, similar to past studies.4,30  
Based on our current mechanistic understanding of ECP, we believe in its potential to treat the highly 
immunosuppressive HNSCC. Over 70 active HNSCC clinical trials involving checkpoint inhibitors 
directed against PD-1 and CTLA-4 are currently underway.31 Though response rates to PD-1 inhibitors 
pembrolizumab and nivolumab remain below 20%, they have demonstrated dramatic improvements in 
median overall survival compared with standard of care therapy.31 Nonetheless, absolute median survival 
is still low.31 Thus, ECP offers a unique, exciting synergy with checkpoint inhibitors by directing an 
adaptive immune response across numerous undefined, patient-specific neoantigens5 while 
simultaneously avoiding tumor-microenvironment mediated anergy.2 
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Figure 1. Flow cytometry confirms large viable populations of anti-HPV16 E7(11-20)  and anti-
HPV16 E7(11-20) CD8 T cells following rapid expansion (REP). Common abbreviations/stains: SSC = 
side scatter; FSC = forward scatter; zombie-APC-Cy7 (live-dead); CD8-PacBlue; CD3-APC. (A) REP 
generated a viable 67% pure anti-HPV16 E7(11-20) CD8 T cell population. Specific stain: E7(11-20) 
dextramer-PE. (B). REP generated a viable ~95% pure anti-HPV16 E7(11-19) CD8 T cell population. 
Specific stains: murineTCR-beta (mTCR-beta) –FITC; CD4-PE-Cy5.5. 
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Figure 2. IFNg ELISA results following 72 
hour CD8 T cell incubation with various 
antigens. No antigen presenting cell is present 
and thus, only short peptide (SP) should directly 
be able to stimulate the TCR. Cognate SP 
appropriately stimulates CD8 T cells. 
Statistically significant IFNg production is 
relative to the T cell only group without antigen 
(ie “null”). Statistically significant (ie *p<0.05) 
bars are displayed. (A) E7(11-20) CD8 T cells are 
exclusively stimulated in the presence of E7(11-20) 
SP and not other peptides/nanoparticle 
combinations, p=0.012. (B) E7(11-20) CD8 T cells 
are exclusively stimulated in the presence of 
corresponding short peptide (SP) again, 
(p<0.0001), and not cell lines. (C)  E7(11-19) CD8 
T cells are stimulated in the presence of E7(11-19) 
SP (****p<0.0001) and LP (***p<0.001), but 
not other peptides and cell lines. LP likely 
directly stimulated TCRs following proteolytic 
degradation into SP (see discussion). 
C. 
A. 
B. 
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Figure 3. IFNg ELISA results following 72 hour PBMC incubation with various antigens (Ags) 
during testing of the E7(11-20) system. Because there is no epitope-specific CD8 T cell line to respond to 
Ag cross-presentation, PBMC + Ag IFNg provides a sense of non-epitope related IFNg production. 
Results above are from 3 different donors. Plate-passaged PBMCs (PP) are compared with non-plate-
passaged PBMCS (no PP). PLGA nanoparticle (NP) encapsulated peptides are included. (A) In the 
PBMC + peptide Ag incubation, maximal IFNg was 1272pg/ml from the LP NP group. (B) In the PBMC 
+ cellular Ag incubation, maximal IFNg was 560pg/ml from the SP group. These values served as 
“background noise” (dotted lines) for Figure 4. 
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Figure 4. IFNg ELISA results following 72 hour co-culture of PBMC and CD8 T cell with various 
antigens (Ags) during testing of the E7(11-20) system. Overall, there was nonspecific IFNg production in 
the E7(11-20) system. IFNg should be released upon APC internalization/processing/cross-presentation of 
E7+ antigen (Ag) or direct stimulation of CD8 T cell receptor (ie with short peptide). Antigens: gp100 
(melanoma peptide; a negative control); E7(11-20) short peptide (SP); E7(1-30) long peptide (LP); normal 
human fibroblast and fibroblasts expressing E6 and E7 proteins (NHF, NHF T+ respectively); SCC90 
(naturally expressing E7); SCC61 T- and SCC61 T+ (naturally non-E7 expressing and transfected to 
express high levels of E7, respectively). PLGA nanoparticle (NP) encapsulated peptides are included. 
Statistically significant IFNg production is relative to the group without antigen (ie “null”). (A) There was 
non-specific IFNg production in E7+ peptide Ag sources (p>0.98). The nanoparticle effect did not 
enhance Ag cross-presentation (p>0.98). The plate-passage effect did not enhance T cell stimulation 
(p>0.98). (B) There was non-specific IFNg production in cellular E7+ Ag sources (p>0.98). The plate-
passage effect did not enhance T cell stimulation (p>0.98). 
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Figure 5. Preliminary IFNg ELISA results of the E7(11-19) 
system following overnight PBMC-antigen incubation 
and 72 hour PBMC + CD8 T cell co-culture. (A) PBMC + 
E7(11-19) CD8 T cell (“PBMC + E7”) was incubated with 
E7(11-19) short peptide (“[11-19]”) or E7(1-30) long peptide 
(“LP”). Relative to the no antigen control group, addition of 
SP and LP resulted in significant T cell stimulation (>40x 
and >50x IFNg, respectively; ****p<0.0001 for both). LP 
produced significantly more IFNg than SP (*p<0.05). (B) 
PBMC + E7(11-19) CD8 T cell + E7 expressing SCC61 
(SCC61 T+) or control non-E7 expressing SCC61(SCC61 
T-) (C) are compared. The effects of platelet depletion (“pl-
”) and monocyte isolation (“mono+”) were also investigated. 
An antigen-specific CD8 T cell response was confirmed by 
significant IFNg production in only the SCC61T+ groups; 
specifically, only platelet-containing (“pl+”) PBMC and 
monocyte SCC61 T+ groups significantly produced IFNg 
(p<0.0001). These results underscore critical ECP variables 
(ie monocytes as the antigen presenting cell progenitor and 
platelets) needed for efficient antigen cross-presentation. 
Non-statistically significant differences (“n.s.”; p>0.05) are 
highlighted with bars. 
SCC61 T+ SCC61 T- 
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Figure 6. IFNg ELISA results following 72 hour PBMC incubation with various antigens (Ags) during 
testing of the E7(11-19) system. Overall, co-cultures suggested Ag-specific CD8 T cell stimulation. Critical 
Transimmunization (TI) components were investigated including platelet depletion (“PLT-”) and the 
absence of TI (ie no plate-passage of PBMCs & no Ag overnight incubation). Antigens: SIINFEKL 
(negative peptide control); E7(11-19) short peptide (SP); E7(1-30) long peptide (LP); SCC90 (naturally 
expressing E7); SCC61 T- and SCC61 T+ (naturally non-E7 expressing and transfected to express high 
levels of E7, respectively). Negative control groups (null and SIINFEKL) produce comparably low IFNg 
(p>0.78). Statistically significant IFNg production with respect to the corresponding negative control group 
is denoted in red asterisks above the experimental group. Peptide groups were compared to the null group 
while tumor groups were compared to SCC61 T- (E7 negative) to account for potential DAMP (Damage-
associated Molecular Patterns) non-Ag specific stimulation from dying tumor cells. Blue asterisks denote 
statistically significant differences within an Ag group, to determine whether TI variables affect Ag cross-
presentation. With respect to peptides, SP (positive control) and LP (PLT-/TI- & PLT+/TI-) groups produced 
significant IFNg (p<0.0001). With respect to tumor cells, only the PLT+/TI+ SCC61 T+ group produced 
high levels of IFNg (p<0.0001), while SCC90 produced comparable (p>0.09) or less (PLT-/TI+, p=0.039) 
IFNg than corresponding SCC61 T- groups. TI protocol modifications resulted in significant differences 
within SP (p<0.017) and LP (p<0.003) groups, but not according to the expected trend (see discussion). TI 
protocol modifications results in significant differences within the SCC61 T+ group; following the expected 
trend, PLT+/TI+ resulted in superior cross presentation relative to PLT+/TI- (p=0.001), PLT-/TI+ 
(p<0.0001), and PLT-/TI- (p<0.0001). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. 
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Figure 7. Inflammatory maturation MoDC markers were quantified using flow cytometry. After 
overnight incubation, inflammatory markers of platelet-depleted (PLT-) and platelet-containing (PLT+) 
monocytes that had undergone TI (ie plate-passage and overnight incubation) with long peptide (LP) or 
with SCC61 T+ were compared to monocytes from fresh PBMCs. Monocytes were identified on the basis 
of CD14+/CD11c+ populations from live, singlet PBMCs. Surface markers (HLA-DR, HLA-ABC, CD-
86, CD-83, PLAUR, ICAM) were plotted as fold-change in mean fluorescent intensity (MFI) relative to 
fresh monocytes (ie value of 1 suggests MFI equal to that of fresh monocytes). Percentage of positive 
monocytes was used to track populations expressing intracellular chemokines or surface CD80. Overall, 
platelet and TI factors generally resulted in an increased expression of every inflammatory marker 
(exceptions: MCP-1 for platelets, HLA-ABC for TI). Notably, SCC61 T+ monocytes showed distinct 
upregulations in CXCL5 and PLAUR but a relative decreased expression in surface markers (see 
discussion). 
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Figure 8. T cells upregulate PD-1 following OKT-3/IL-2 stimulation. These results suggest a working 
system to track patients’ unknown neoantigen-reactive T cells in future experiments, as previously 
described in the literature. PD-1 expression in T cells following 2 day stimulation of PBMCs with OKT-3 
(30ul of 1mg/ml stock) and 1300IU/ml IL-2 (“Stim(+)”) was compared to 2 day unstimulated PBMCs 
(“Stim(-)”). FMO = fluorescence minus one. Ab = full staining panel. PD-1 positivity was calculated as 
the difference between Ab and FMO per population. For CD8 T cells, stimulation resulted in a 43% 
increase in the PD-1+ population (7% PD-1+ in unstimulated cells versus 50% in stimulated cells). For 
CD4 T cells, stimulation resulted in a 45% increase in the PD-1+ population (12% PD-1+ in unstimulated 
cells versus 57% in stimulated cells). Stains: PD-1-PacBlue, live-dead “zombie”-APC-Cy7, CD3-PE, 
CD4-APC, CD8-FITC. FSC = forward scatter; SSC = side scatter. 
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Supplementary Figure 1. Schematic for CD8 T cell transduction, purification, and rapid expansion. 
CD8 T cells were isolated from a healthy HLA-A2+ donor and transduced with an MSGV1 retrovirus 
encoding the E7(11-19) T cell receptor (TCR) plasmid. After incubation with the virus, CD8 T cells should 
co-express high avidity E7(11-19) TCR and can be identified based on the murine TCR-β (mTCRb) constant 
region. The transduced population of CD8 T cells was sorted with flow cytometry for CD3/CD8/mTCRb 
triple positivity and subsequently rapidly expanded. Thus, a large, high purity E7(11-19) CD8 T cell 
population was produced. 
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Supplementary Figure 2. Schematic for Transimmunization (TI) Experiments. PBMCs, containing 
antigen-presenting cell (APC) progenitors, and platelets (PLTs) are isolated from an HLA-A2+ donor. In 
tumor cell antigen groups, PUVA-treated tumor cells are plate-passaged with PBMCs. In peptide antigen 
groups, peptides are added to the overnight incubation dish containing PBMCs after plate passage. For 
both tumor cell and peptide antigen groups, after overnight incubation, PBMCs are co-cultured with 
epitope-specific CD8 T cells for 72 hours in 96-well plates. After this period, supernatant is collected for 
IFNg ELISA. If APC cross-presentation is successful, then stimulated CD8 T cells should produce IFNg. 
 
 
 
 
 
